SLE and DVT Risk
Magnitude of Risk
- SLE is an independent risk factor for both arterial and venous thrombotic events, according to the MMWR Recommendations and Reports and Annals of the Rheumatic Diseases 1, 2
Risk Stratification and Clinical Implications
- The American College of Physicians and other guideline societies imply that SLE patients with positive antiphospholipid antibodies, particularly those with high-risk profiles, may benefit from low-dose aspirin for primary thrombosis prevention, as suggested by Annals of the Rheumatic Diseases 2, 4, 5
- The European League Against Rheumatism recommends that additional anticoagulant treatment with low-molecular-weight heparin should be considered during high-risk periods such as surgery or prolonged immobilization, as stated in Annals of the Rheumatic Diseases 2, 4
- For SLE patients who develop DVT, the American Heart Association suggests that vitamin K antagonists (warfarin with target INR 2-3) are preferred over direct oral anticoagulants (DOACs), according to Praxis Medical Insights and Annals of the Rheumatic Diseases 2, 4, 6
Additional Risk Factors and Prevention
- Persistent high disease activity, lupus nephritis, glucocorticoid use, and nephrotic syndrome with hypogammaglobulinemia are SLE-related factors that increase thrombotic risk, as reported by Annals of the Rheumatic Diseases 2, 4, 5
- The U.S. Medical Eligibility Criteria assigns Category 4 (unacceptable health risk) to combined hormonal contraceptives in SLE patients with positive or unknown antiphospholipid antibodies, as stated in MMWR Recommendations and Reports 1, 7
- Hydroxychloroquine should be maintained as cornerstone therapy, as it reduces disease flares and has protective effects against thrombosis, according to Praxis Medical Insights 6, 8